Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

S-P gets exclusive US rights to Millennium's Integrilin

Executive Summary

Schering-Plough is restructuring its license agreement for Millennium Pharmaceuticals' cardiovascular drug Integrilin (eptifibatide) and will now assume exclusive US development and commercialization rights. The companies have co-promoted the drug since 2002, when Millennium bought Cor Therapeutics; Cor had been co-promoting Integrilin with S-P since 1998 under terms of a 1995 deal.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies